Deal facts
- Buyer
- New Horizon Pharma B.V.
- Target
- Phatebo GmbH
- Deal value
- EUR 2,150,000
- Announced
- 9 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- Germany
- Consideration
- cash
Sources
ZeroStack Corp. disclosed in a Form 8-K, accepted by the SEC on 9 November 2026, that on 3 November 2026 it signed a Share Purchase and Transfer Agreement with New Horizon Pharma B.V. and Phatebo GmbH. Under the agreement ZeroStack, which owns 100% of Phatebo, agreed to sell all of Phatebo's issued and outstanding shares to New Horizon Pharma for an aggregate purchase price of €2,150,000. The agreement covers 50,016 shares with a nominal value of EUR 1.00 each, so this is a sale of the company itself, not of selected assets. ZeroStack was formerly named Flora Growth Corp.
Phatebo is based in Hilzingen, Germany. The agreement says it holds a wholesale authorisation under Section 52a of the German Medicinal Products Act (AMG) and that its business is the wholesale trade in pharmaceutical products and medical devices and the supply of investigational, comparator and ancillary medicinal products for clinical trials. The agreement's recitals say that on 24 September 2026 HRV Global Life Sciences Private Limited, the indirect sole shareholder of the purchaser, issued a non-binding indicative term sheet for a controlling stake in Phatebo.
The price is a fixed amount that is not adjusted for cash, financial debt, working capital or any other balance sheet item. The economic effective date is the locked box date of 31 December 2025. The price falls due on the fifteenth business day after all closing conditions are met or waived. Of that sum, EUR 152,709.44 is paid to Phatebo on ZeroStack's behalf in repayment of a loan, and the remainder goes to the seller's account in US dollars. That remainder is fixed at USD 2,240,161.09, using the European Central Bank rate of EUR 1.00 = USD 1.1216 published on 2 November 2026. If the due date falls after 31 March 2027, the price bears interest at 4% a year from 1 April 2027, except where the delay results from the seller's breach of duty.
The one regulatory condition is foreign direct investment clearance from Germany's Federal Ministry for Economic Affairs and Energy (BMWE), which the agreement says cannot be waived. The buyer must notify the BMWE within ten business days of signing. If the conditions are not met by 30 June 2027, or by 31 December 2027 if the buyer notified in time and the BMWE has opened a review that has not concluded by then, either the seller or the purchaser may withdraw, provided it is not responsible for the failure. The share transfer is conditional on the FDI clearance and on payment of the purchase price in full.
Deal timeline
1 update- Firm intention
New Horizon Pharma B.V. firm intention to acquire Phatebo GmbH
Item 1.01 Entry into a Material Definitive Agreement. On November 3, 2026, ZeroStack Corp. (the "Company") entered into a Share Purchase and Transfer Agreement (the "Purchase Agreement") with New Horizon Pharma B.V. (the "Purchaser") and Phatebo GmbH ("Phatebo"), pursuant to which the Company agreed to sell to the Purchaser all of the issued and outstanding shares of Phatebo for an aggregate purch
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
New Horizon Pharma B.V.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive